Mucosal and systemic immunization with a novel attenuated pneumococcal vaccine candidate confer serotype independent protection against Streptococcus pneumoniae in mice

Vaccine

Volumn 32, Issue 33, 2014, Pages 4179-4188

  Wu, Kaifeng ^a   Yao, Run ^b   Wang, Hong ^a   Pang, Dan ^a   Liu, Yusi ^a   Xu, Hongmei ^a   Zhang, Shuai ^a   Zhang, Xuemei ^a   Yin, Yibing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Live attenuated vaccine; Mucosal immunization; Protection; Streptococcus pneumoniae

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIVE VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; TEICHOIC ACID; VIRULENCE FACTOR; BACTERIUM ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VIVO STUDY; MOUSE; MUCOSAL IMMUNIZATION; MURINE MODEL; NASOPHARYNX; NONHUMAN; PHENOTYPE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC IMMUNIZATION; VIRUS VIRULENCE; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MICROBIOLOGY; MUCOSAL IMMUNITY; PNEUMOCOCCAL INFECTIONS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL LOAD; CROSS PROTECTION; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; VACCINES, ATTENUATED;

EID: 84903464530     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.019     Document Type: Article

References (50)

1. Organization WH. Global immunization data; 2008. p. 2.
2. Balakrishnan I., Crook P., Morris R., Gillespie S.H. Early predictors of mortality in pneumococcal bacteraemia. J Infect 2000, 40:256-261.
3. Luby S.P., Brooks W.A., Saha S.K., el-Arifeen S., Naheed A., Sack D., et al. Use of multiple surveillance modalities to assess the epidemiology of Streptococcus pneumoniae infection in Bangladesh. Clin Infect Dis 2009, 48(Suppl. 2):S97-S102.
4. Karlowsky J.A., Thornsberry C., Jones M.E., Evangelista A.T., Critchley I.A., Sahm D.F. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003, 36:963-970.
5. Hoban D., Waites K., Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003, 45:251-259.
6. Song J.H., Jung S.I., Ko K.S., Kim N.Y., Son J.S., Chang H-H., et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP Study). Antimicrob Agents Chemother 2004, 48:2101-2107.
7. Liu Y., Wang H., Chen M., Sun Z., Zhao R., Zhang L., et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis 2008, 61:256-263.
8. Lo W.T., Wang C.C., Yu C.M., Chu M.L. Rate of nasopharyngeal carriage, antimicrobial resistance and serotype of Streptococcus pneumoniae among children in northern Taiwan. J Microbiol Immunol Infect 2003, 36:175-181.
9. Chiu S.S., Ho P.L., Chow F.K.H., Yuen K.Y., Lau Y.L. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother 2001, 45:2765-2770.
10. Zhou L., Ma X., Gao W., Yao K.H., Shen A.D., Yu S.J., et al. Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010. BMC Microbiol 2012, 12:1471-2180.
11. Novak R., Henriques B., Charpentier E., Normark S., Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999, 399:590-593.
12. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Engl J Med 1991, 325:1453-1460.
13. Jacobs M.R. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med 2004, 117:3-15.
14. Calix J.J., Nahm M.H. A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene. J Infect Dis 2010, 202:29-38.
15. Giefing C., Meinke A.L., Hanner M., Henics T., Bui M.D., Gelbmann D., et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008, 205:117-131.
16. Scott J.A. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007, 25:2398-2405.
17. Veenhoven R., Bogaert D., Uiterwaal C., Brouwer C., Kiezebrink H., Bruin J., et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 2003, 361:2189-2195.
18. Bogaert D., van Belkum A., Sluijter M., Luijendijk A., de Groot R., Rümke H.C., et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004, 363:1871-1872.
19. Thompson A., Gurtman A., Patterson S., Juergens C., Laudat F., Emini E.A., et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine 2013, 31:5289-5295.
20. Roche A.M., King S.J., Weiser J.N. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 2007, 75:2469-2475.
21. Swiatlo E., Ware D. Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol Med Microbiol 2003, 38:1-7.
22. Billips B.K., Yaggie R.E., Cashy J.P., Schaeffer A.J., Klumpp D.J. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis 2009, 200:263-272.
23. Au C.C., Eisenstein T.K. Nature of the cross-protective antigen in subcellular vaccines of Streptococcus pneumoniae. Infect Immun 1981, 31:160-168.
24. Kim E.H., Choi S.Y., Kwon M.K., Tran T.D., Park S.S., Lee K.J., et al. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine 2012, 30:2008-2019.
25. + T-cell dependent class switching and provides serotype independent protection against acute otitis media. EMBO Mol Med 2013, 10.1002/emmm.201202150.
26. Wu K., Zhang X., Shi J., Li N., Li D., Luo M., et al. Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun 2010, 78:1276-1283.
27. Zhang Q., Xu S.X., Wang H., Xu W.C., Zhang X.M., Wu K.F., et al. Contribution of ClpE to virulence of Streptococcus pneumoniae. Can J Microbiol 2009, 55:1187-1194.
28. Zhang J.R., Idanpaan-Heikkila I., Fischer W., Tuomanen E. Pneumococcal licD2 gene is involved in phosphorylcholine metabolism. Mol Microbiol 1999, 31:1477-1488.
29. Pearce B.J., Naughton A.M., Masure H.R. Peptide permeases modulate transformation in Streptococcus pneumoniae. Mol Microbiol 1994, 12:881-892.
30. Weischenfeldt J., Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. Cold Spring Harb Protoc 2008, 3(12):1-7.
31. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., Briles D.E. Intranasal immunization of mice with PspA (Pneumococcal Surface Protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997, 175:839-846.
32. Cao J., Chen D., Xu W., Chen T., Xu S., Luo J., et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 2007, 25:4996-5005.
33. Romero-Steiner S., Libutti D., Pais L.B., Dykes J., Anderson P., Whitin J.C., et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997, 4:415-422.
34. Byun E.H., Kim W.S., Kim J.S., Won C.J., Choi H.G., Kim H.J., et al. Mycobacterium paratuberculosis CobT activates dendritic cells via engagement of Toll-like receptor 4 resulting in Th1 cell expansion. J Bio Chem 2012, 287:38609-38624.
35. Ferreira D.M., Darrieux M., Oliveira M.L.S., Leite L.C.C., Miyaji E.N. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein A is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a Ratio and proinflammatory cytokine production. Clin Vaccine Immunol 2008, 15:499-505.
36. Moscoso M., Garcia E. Transcriptional regulation of the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae: a bioinformatic analysis. DNA Res 2009, 16:177-186.
37. Ko K.S., Park S., Oh W.S., Suh J.Y., Oh T., Ahn S., et al. Comparative analysis of growth-phase-dependent gene expression in virulent and avirulent Streptococcus pneumoniae using a high-density DNA microarray. Mol Cells 2006, 21:82-88.
38. Tomasz A. Biological consequences of the replacement of choline by ethanolamine in the cell wall of Pneumococcus: chanin formation, loss of transformability, and loss of autolysis. Proc Natl Acad Sci USA 1968, 59:86-93.
39. Darrieux M., Goulart C., Briles D., Leite L.C. Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol 2013, 29:1-11.
40. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001, 69:4870-4873.
41. Benton K.A., Paton J.C., Briles D.E. The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb Pathog 1997, 23:201-209.
42. McNeela E.A., Burke Á., Neill D.R., Baxter C., Fernandes V.E., Ferreira D., et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010, 6:e1001191.
43. Douce G., Ross K., Cowan G., Ma J., Mitchell T.J. Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae. Vaccine 2010, 28:3231-3237.
44. Travassos L.H., Girardin S.E., Philpott D.J., Blanot D., Nahori M.A., Werts C., et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004, 5:1000-1006.
45. Gisch N., Kohler T., Ulmer A.J., Muthing J., Pribyl T., Fischer K., et al. Structural reevaluation of Streptococcus pneumoniae Lipoteichoic acid and new insights into its immunostimulatory potency. J Biol Chem 2013, 288:15654-15667.
46. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181.
47. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4:e1000159.
48. Briles D.E., Hollingshead S.K., Nabors G.S., Paton J.C., Brooks-Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000, 19(Suppl. 1):S87-S95.
49. Kane M. Unsafe injections. Bull World Health Organization; 1998, 99-100.
50. Kowalko J.E., Sebert M.E. The Streptococcus pneumoniae competence regulatory system influences respiratory tract colonization. Infect Immun 2008, 76:3131-3140.